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Comparing Screening and Treatment of Bacterial Vaginosis 
and Pregnancy Outcomes
Stephanie Severson PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
• Evidence shows that bacterial vaginosis (BV) can lead to poor 
perinatal outcomes.
• The goal of this project is to answer the question of which 
pregnant patients should be screened for BV and does 
identification and treatment of BV during pregnancy improve 
perinatal outcomes. 
• Due to variability in a multitude of factors, a generalized 
recommendation is difficult to make. Lack of recommendations 
are largely due to harm of treatment in those who were 
misdiagnosed.
• The development of polymerase chain reaction (PCR) has the 
capability to reduce misdiagnosis.
• Newer studies have shown benefit of early screening and 
treatment and the use of clindamycin over the traditional 
treatment of metronidazole.
• An online search of PubMed, CINHAL, and Cochrane databases 
in the past 10 years yielded meta-analyses, systematic reviews, 
random control trials, and cohort studies. Additional sources found 
using reference lists. Search terms utilized included; bacterial 
vaginosis, vaginitis, pregnancy, pregnant, miscarriage, screening, 
pre-term, and asymptomatic.
Abstract
• BV is the most common lower genital tract syndrome in women of 
reproductive age and research has shown that it is linked to poor 
perinatal outcomes. There are varying opinions on which pregnant 
patients should be screened for BV and what treatments should 
be used. 
Statement of the Problem
• USPSTF guidelines are currently under revision.
• BV can now be diagnosed using polymerase chain reaction 
(PCR). It is predicted to have a sensitivity of 100% and specificity 
of 93%.
• Much of the research does not include if other infections were 
present at the time of diagnosis or if the patients have had history 
of vaginitis or STDs. 
• It appears Candida, Trichomonas, and other STDs can play a role 
in miscarriage and can  also contribute to the patient being 
asymptomatic to a BV infection.
• Further studies are needed that focus on using PCR for diagnosis, 
early screening; prior to the closure of the decidua, and 
clindamycin for treatment. 
• Screening may also be beneficial for those struggling with 
preclinical miscarriage.
Applicability to Practice 
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Research Question
• Would screening and treatment for asymptomatic BV improve 
perinatal outcomes?
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Literature Review
• The 2008 USPSTF and 2015 CDC guidelines recommend 
against routine screening of pregnant women for BV based on 
lack of consistent benefit and possible risk of harm.
• Historically, diagnosis is made by Amsel or Nugent criteria.
• Intermediate flora; Nugent score of 4-6 has also been associated 
with poor perinatal outcomes.
• SOGC guidelines states vaginal therapy is not recommended for 
the indication of preventing adverse pregnancy outcomes.
Incidence rate of bacterial vaginosis and
poor perinatal outcomes
• Koumans et al found no statistical significance for preterm 
delivery between women treated for abnormal flora or BV vs 
women with normal flora.
• A retrospective study done by McNamee et al found 
chorioamnionitis in 94% of preterm deliveries (PTD) prior to 24 
weeks gestation.
• According to Nelson et al, there is a relationship between 
asymptomatic BV and less stress, history of STDs, & higher 
quantity of Mobiluncus.
• Usher-Pines et al found lower levels of Lactobacillus were 
associated with African American race and douching. 
o Higher amounts of Mobiluncus & Gardneralla were correlated 
with African American race, single women, & smokers.
• A meta-analysis by Van Oostrum et al found a higher incidence 
of abnormal flora and BV among infertility patients & an 
association between BV and preclinical pregnancy loss (p<0.01).
Treatment of bacterial vaginosis and effect 
on perinatal outcomes
• A Cochrane review of BV positive women done by Brocklehurst 
et al found treatment with clindamycin reduced the incidence of 
late miscarriage. PTBs <37 weeks were reduced when 
intermediate flora was treated with clindamycin.
• Haahr et al made a strong recommendation against treatment for 
BV positive women using metronidazole to reduce risk of PTD. If 
clindamycin was started before 20 weeks gestation there was a 
slight reduction in pPROM.
• Lamont et al found oral clindamycin had a 61% reduction in PTD 
<37 weeks and a 27% reduction with clindamycin vaginal cream.
• Workowskit & Bolan recommend treatment for all symptomatic 
patients. Treatment of asymptomatic high risk patients may be 
beneficial. Treatment of asymptomatic low risk patients remains 
unclear.
• A Cochrane review done by Sangkomkamhang et al showed 
screening and treatment for antenatal lower genital infections 
reduces preterm birth.
Introduction
• BV occurs when there is a disruption of the normal flora; 
Lactobacilli and an overgrowth of anaerobic bacteria.
• Chorioamnionitis, preterm delivery (PTD), preterm rupture of 
membranes (PROM), and  miscarriage have all been associated 
with positive bacterial vaginosis during pregnancy. 
• BV is present in 20-50% of women during pregnancy and most 
cases are asymptomatic. 
• Up to 50% of BV cases clear without treatment but others may 
recur after treatment. 
• Alteration in vaginal flora increases risk of acquiring other STDs
• First line treatment for BV positive pregnant women is oral 
metronidazole or clindamycin.
• Clindamycin has a broader range against atypical mycoplasma 
and Mobiluncus compared to the traditional treatment of 
metronidazole.
Discussion
• The consensus remains against a screening and treatment 
protocol for all pregnant women.
• Of the treatment trials used for the USPSTF recommendations, 
one found asymptomatic women who were treated with 
metronidazole had increased risk of preterm delivery. 
• The other treatment trials used for USPSTF recommendations, 
found no statistically significant adverse effects to pregnancy 
outcomes.
• “Vaginal contents are in communication with the uterus until the 
fusion of the decidua capsularis with the decidua paretalis at 14-
16 weeks of gestation". (Koumans et al. 2011, p. 1021)
• Many of the current studies used to make recommendations 
involve screening that took place after 14-16 weeks gestation.
• BV appears to have a higher incidence among women with 
infertility and is associated with preclinical pregnancy loss.
• Risk factors for BV include; history of miscarriage, PTD, or 
infertility. Age < 30, African American race, recent history or 
current smoker, increased number of sexual partners, history of 
STDs, douching, high school level of education or less. 
• Alteration in vaginal flora increases risk for acquiring other 
sexually transmitted diseases.
Number of spontaneous PTD < 37 weeks. 
(p=0.0001)
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Curved gram-variable rods 
0 4 + 0 0 
1 3 + 1 + 1 + or 2 + 
2 2 + 2 + 3 + or 4 + 
3 1 + 3 + 
4 0 4 + 
Nugent scoring system (0-10) for 
gram-stained vaginal smears
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Screening & treatment of asymptotic BV, 
Candidiasis, & Trichomonas 
